ABSTRACT. The purpose of this study was to identify differentially expressed (DE) genes and biological processes associated with changes in gene expression in autism. We performed a meta-analysis using new publicly available Gene Expression Omnibus (GEO) datasets of autism. We performed Gene Ontology (GO) enrichment analyses and pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG). Ten GEO datasets, including 364 cases and 248 controls, were available for the meta-analysis. We identified 3105 genes that were consistently DE in autism (1425 upregulated and 1680 downregulated genes). We also found that 7 genes were associated with phospholipase A2 (PLA2), including LYPLA2P1, PLA2G4D, PNPLA2, LYPLA2, PLA2G6, PLA2G7, and PLA2G5. We found GO terms for molecular functions significantly enriched in structural constituent of ribosome (GO: 0003735, P = 1.87-E06) and transcription regulator activity (GO: 0030528, P = 8.86E-04), while for biological processes, the enriched GO terms were involved in translational elongation (GO: 0006414, P = 1.74E-12) and the response to cytokine stimuli (GO: 0034097, P = 2.76E-05). The most significant pathway in our KEGG analysis was the ribosome pathway (P = 7.90E-2147 Meta-analysis of gene expression data in autism ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (1): 2146-2155 (2015) 12). Our meta-analysis identified genes that were consistently DE and biological pathways associated with gene expression changes in autism.
INTRODUCTION
Autism is a common, highly heritable neuro-developmental condition characterized by marked genetic heterogeneity (Durand et al., 2007) . Various etiologies have been suggested for this complex syndrome. Though it is associated with a high degree of heritability, the specific genes responsible for autism remain unknown. Various other factors have been implicated, including immunological (Ashwood et al., 2006) , neurological (Hashimoto et al., 1993) , and environmental (London, 2000) factors. Thus, a fundamental question is whether autism represents an etiologically heterogeneous disorder in which a myriad genetic or environmental risk factors perturb common underlying molecular pathways in the brain (Geschwind, 2008) . However, in contrast with many other brain disorders, including neurodegenerative diseases such as Parkinson's or Alzheimer's diseases, autism lacks a clear unifying pathology at the molecular, cellular, and systems levels.
Emerging evidence implies that abnormal fatty acid metabolism plays a contributing role in autism pathology. Recent literature suggests that fatty acid homeostasis may be altered in autism as a result of insufficient dietary supplementation, genetic defects, function of enzymes involved in their metabolism, or influence of various environmental agents such as infections, inflammation, or drugs. Phospholipase A2 (PLA2) is an enzyme involved in maintaining membrane phospholipids. There are 3 major types of PLA2 enzymes: the calcium-dependent group IV cytosolic PLA2, the group II secretory PLA2, and the group VI calcium-independent PLA2 (Sun et al., 2004) . Elevated levels of PLA2 in red blood cells have been associated with neuropsychiatric disorders such as schizophrenia, depression, bipolar disorder, dyslexia, and autism (Horrobin and Bennett, 1999; Bell et al., 2004) .
Determining global levels of gene expression regulation may be particularly important for understanding the pathological basis of diseases such as autism, in which multiple systems are affected. Alterations at the global level of gene expression regulation may be shared across systems, even when the tissue-specific genes affected by these global changes differ. Highthroughput genomics technologies have improved our understanding of the complex interactions and networks involved in disease development. Microarrays measure the expression of thousands of genes simultaneously on a genome-wide scale (Golub et al., 1999) . Alterations in gene profiles can be correlated to altered gene functions and biochemical activities. Microarray is a powerful tool that has rapidly increased as an investigational method in medical research.
Identification of gene expression signatures that differentiate the disease state from healthy controls is dependent on samples, sample size, heterogeneous data sets, and reproducibility (Ramasamy et al., 2008) . Although many microarray studies have provided lists of differentially expressed (DE) genes, there are inconsistencies among studies resulting from limitations such as small sample sizes (Siddiqui et al., 2006) . Data integration techniques, such as meta-analyses, combine available data and integrate information from multiple independent but related microarray studies to identify significant genes (Feichtinger et al., 2012) . Combining data from various studies can enhance the reliability and generalizability of the results (Ramasamy et al., 2008) and can be used to more precisely estimate gene expression. In particular, the benefit of increased statistical power can help to overcome the limitation of microarray studies. In this study, we used a new method to perform a meta-analysis of expression data of multiple gene expression data sets. To overcome the limitations of individual studies, resolve inconsistencies, and reduce the likelihood of random errors revealing false-positive or false-negative associations, we performed a microarray meta-analysis to identify DE genes and biological processes associated with gene expression changes in autism.
MATERIAL AND METHODS

Identification of eligible autism
ASD gene expression datasets
We first queried PubMed and related databases for expression profiling studies comparing autism and normal control tissues (NT). The following key words and their combinations were used: "autism, gene expression, microarray, genetics". In addition, the Gene Expression Omnibus database (GEO, http://www.ncbi.nlm.nih.gov/geo) was also searched to identify any other relevant studies. The search results were limited to those published between 2000 and March 2013. We only retained the original experimental articles that analyzed gene expression profiling of autism and NT. Non-human studies, review articles, and integrated analysis of expression profiles were excluded. We conducted this meta-analysis in accordance with the guidelines provided in the PRISMA statement (The PRISMA Checklist S1). Data were extracted from the original studies by 2 independent reviewers. Any discrepancies between reviewers were resolved by consensus or consultation with a third reviewer. The following information was extracted from each identified study: GEO accession number, sample type, platform, number of cases and controls, references, and gene expression data.
Data preprocessing
Normalization is important for comparing microarray data sets. The heterogeneity of different datasets caused by using different platforms, different gene nomenclature, and different control tissues may make it difficult to directly compare studies. Thus, a global normalization method for minimizing inconsistency should be used. For this purpose, we used the Z-score transformation approach to calculate the expression intensities for each probe of the gene expression profiles. Z-scores were calculated according to the formula: where x i represents raw intensity data for each gene; represents average gene intensity within a single experiment, and d represents standard deviation (SD) of all measured intensities.
Statistical analysis
The significance analysis of the microarray software was then used to identify the DE genes between disease and control samples. This procedure combines the calculation of a Student t-test statistic value for each gene with subsequent permutation analysis and false discovery rate (FDR) calculation. To obtain the best balance between the number of significant calls and the lowest FDR for the dataset tested, we selected genes showing at least 2-fold changes and an FDR less than 0.05 as significantly DE.
Functional classification of DE genes
To examine the biological significance of DE genes, we performed Gene Ontology (GO) enrichment analysis to investigate their functional distribution. The online-based software GeneCoDis3 (http://genecodis.cnb.csic.es) was used for this analysis. Fisher's exact test was used at P value < 0.1 and significance level was adjusted by a correction for FDR. In addition, we also performed pathway enrichment analysis based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.
RESULTS
Overview of the studies included
In this study, we identified a total of 10 expression-profiling studies based on our inclusion criteria, which included 612 samples of 364 cases and 248 controls. The characteristics of studies included in this analysis are listed in Table 1 (Nishimura et al., 2007; Gregg et al., 2008; Hu et al., 2009a,b; Alter et al., 2011; Voineagu et al., 2011; Kuwano et al., 2011; Ginsberg et al., 2012) . The data sets for GSE30573 and GSE28521 were examined in the same study, but GSE30573 was RNA -seqdata set, and the data sets we applied were almost microarray data sets except for GSE30573. GEO 
Global changes in gene expression
To identify genetic markers involved in the development and progression of child autism, we determined the probe ID, for a microarray platform that represent a named gene, and the HUGO symbol of that gene, for each data set to the National Center for Biotechnology Information (NCBI) gene ID. The expression value was logarithmically transformed (base 2) and then transformed to a Z-score for global normalization. After filtering the normalized data, 33,502 genes were detected in more than 60% of the samples.
Using the assembled expression compendium, we investigated global shifts in gene expression between child autism and corresponding NTs, respectively. The significance analysis of the microarray method was used to identify DE genes between pathological and control samples. With the threshold of FDR< 0.05 and minimal 2-fold changes, a total of 3105 genes were found to be DE between child autism and NT. Among the 3105 DE genes, 1425 genes were upregulated and 1680 genes were downregulated. Lists of the top 20 most significantly up-or downregulated genes are provided in Tables 2 and 3 , respectively. We also identified 7 genes associated with PLA2, including LYPLA2P1, PLA2G4D, PNPLA2, LYPLA2, PLA2G6, PLA2G7, and PLA2G5 ( 
Functional annotation of DE genes
To gain insight into the biological roles of these DE genes, we performed GO categories enrichment analysis. GO provides a common descriptive framework and functional annotation and classification for gene sets analysis. GO categories are organized into 3 groups: biological process, molecular function, and cellular component. In our study, only the biological process and molecular function categories were considered. Using an FDR < 0.01 threshold, we identified 146 significant enrichments for DE genes. We identified GO terms for molecular functions significantly enriched in structural constituent of ribosome (GO: 0003735, P = 1.87-E06) and transcription regulator activity (GO: 0030528, P = 8.86E-04) (Table 5) , while for biological processes, the enriched GO terms were translational elongation (GO: 0006414, P = 1.74E-12) and response to cytokine stimulus (GO: 0034097, P = 2.76E-05). To further evaluate the biological significance of the DE genes, we also performed a KEGG pathway enrichment analysis (Table 6 ). The most significant pathway in our KEGG analysis was the ribosome pathway (P = 7.90E-12). Furthermore, graft-versus-host disease (P = 9.67E-03) and primary immunodeficiency pathways (P = 3.32E-02) were found to be highly enriched.
KEGG pathway P value Genes
Ribosome 7. 90E-12 LOC729362, LOC441073, LOC728139, LOC644464, RPS11, LOC388339, RPL37A, LOC100129685, RPL38, LOC644934, RPL14, RPS4X, LOC647285, LOC728576, LOC645174, LOC646766, LOC646966, LOC389156, RPL27A, LOC643358, LOC100131205, LOC100129882, RPLP0P2, SNORA7B, RPS19, LOC387867, RPL12P6, RPS4X, LOC729402, RPS6, LOC400652, RPLP2, LOC100128060, RPL18, LOC648729, LOC100129902, LOC389141, LOC730029, LOC389342, LOC440575, LOC642892, RPS10P7, LOC100129424, LOC388556, LOC653156, RPL13, RPL10, LOC440737, RPL7A, LOC100128936, LOC728782, RPS27, LOC388474, LOC391833, RPL10L, RPS21, LOC653737, LOC441034 Graft-versus- 
DISCUSSION
Various genes are DE in individuals with autism, and identifying the most important genes and pathways associated with the disease is very important. We used a meta-analysis approach of DE genes from microarray datasets to identify genes that were consistently DE at a statistically significant level, and performed GO enrichment analysis and pathway analysis using KEGG.
We performed a meta-analysis using 10 publicly available GEO data sets to identify common biological mechanisms involved in the pathogenesis of autism. Nine of these GEO data sets were based on microarray data, while the GSE30573 dataset was from RNA sequencing determined in the same study as GSE28521. In 3 studies, postmortem brain tissue from individuals with autism was analyzed to show that the glutamate neurotransmitter system is altered in patients with autism, while other studies examined blood cells from autistic individuals. We identified genes that were consistently up-or downregulated, showed significant GO enrichment, and pathways associated with autism. A total of3105 genes across the studies were consistently DE in autism (1425 upregulated and 1680 downregulated). Among these 3105 DE genes, 7 genes were associated with PLA2. To identify the biological processes associated with gene expression changes in autism, we performed GO analysis for the DE genes. The most significant enrichment among the list of molecular functions was the GO category of structural constituents of the ribosome (P = 1.87-E06). Other significant GO categories for biological processes included translational elongation (P = 1.74E-12) and the response to cytokine stimulus (P = 2.76E-05). The most significant pathway in our KEGG analysis was ribosome pathway (P = 7.90E-12). Furthermore, the graft-versus-host disease (P = 9.67E-03) and primary immunodeficiency pathways (P = 3.32E-02) were found to be highly enriched.
Using genome-wide differential display approaches, a number of recent studies have highlighted single-nucleotide polymorphisms, copy number variants, and epigenetic factors involved in the dysregulated expression of candidate genes related to autism occurrence (Bill and Geschwind, 2009 ). Putative and known candidates contributing to autism susceptibility are categorized based on the differentiation of neurons (e.g., DISC1, MET, PTEN, and ITGB3), neuronal cell adhesion (e.g., NRXN1, NLGN3, and NLGN4X), transmission of nervous system (e.g., OXTR, SLC6A4, GABRB3, and SHANK3), and regulation of neuronal activity (e.g., FMR1, MECP2, and UBE3A) (Ingram et al., 2000; Martin et al., 2000; Wassink et al., 2001; Jamain et al., 2002; Campbell et al., 2006; Hu et al., 2006; Talebizadeh et al., 2006; Durand et al., 2007) . In this study we identified autism susceptibility genes such as WNT2, EGR2, HOXA1, and SHAK3 among the 3105 differentially expressed genes. One of the underlying biological components of neuro-developmental disorders may involve dysregulation of phospholipid metabolism. Therefore, we also identified genes associated with PLA2, including LYPLA2P1, PLA2G4D, PNPLA2, LYPLA2, PLA2G6, PLA2G7, and PLA2G5, among these DE genes identified. Evidence has accumulated regarding elevated plasma levels of PLA2 in schizophrenia patients compared with healthy controls. Three single-nucleotide polymorphisms in the gene encoding for cytosolic PLA2 have been linked to schizophrenia and were found to play a role in the etiology of this disorder (Wei et al., 1998; Tao et al., 2005) . Interestingly, the genes encoding human calcium-independent PLA2 and secretory PLA2 map to regions on chromosome 8q23-24 and 7q31, respectively (Meyer et al., 1996) , which have been previously linked to autism (Chen et al., 2005; Combi et al., 2010) . This suggests that the altered levels of arachidonic acid and docohexaenoic acid in individuals with autism may be attributed to abnormalities in PLA2. Indeed, significantly increased activity of type IV PLA2 has been reported in the red blood cells of patients with autism and Asperger's syndrome compared to controls, strengthening the hypothesis that abnormal lipid metabolism occurs in autism (Bell et al., 2004 (Bell et al., , 2010 . The increased PLA2 activity in individuals with autism may cause elevated breakdown of polyunsaturated fatty acids and their subsequent reduced incorporation into membrane phospholipids. Overall, the literature suggests a link between abnormalities in PLA2 enzymes and some psychiatric disorders, including autism spectrum disorders, which substantiates the importance of downstream lipid signaling molecules in proper nervous system functioning.
Interestingly, the most significant pathway in our KEGG analysis was the ribosome pathway. Ribosomal proteins play a crucial role in the regulation of protein synthesis. Therefore, their expression must be strictly controlled (Caldarola et al., 2009) . This finding suggests a generalized and non-targeted process and may be a result of deregulation of other pathways. Several lines of evidence have identified a link between ribosome biogenesis and diseases such as cancer, anemia, and aging. A recent review also emphasized that protein synthesis is tightly linked to the regulation of neurological processes and cell growth (Twiss and Fainzilber, 2009 ). Deregulation of genes encoding ribosomal proteins may indirectly reflect an atypical process of neurological development in subjects with autism.
There were some limitations to our study. First, heterogeneity and confounding factors may have distorted our analysis. Clinical samples may be heterogeneous with respect to clinical activity, severity, or gender. Second, there were differences in gene expression between tissues such as the blood and brain that were not taken into account. However, our meta-analysis integrated data from different studies, enabling us to detect genes that would otherwise not have been identified. Despite these limitations, our findings have important implications for the pathophysiology of autism.
